Browse > Article

The Effects of Hoechunyanggyeok-san on hyperglycemia and Dyslipidemia in db/db mice  

Jang, Soo-Young (Dept. of Internal Medicine of Korean Medicine, College of Korean Medicine, Dae-Gu Haany University)
Jung, Yu-Sun (Dept. of Internal Medicine of Korean Medicine, College of Korean Medicine, Dae-Gu Haany University)
Shin, Hyeon-Cheol (Dept. of Internal Medicine of Korean Medicine, College of Korean Medicine, Dae-Gu Haany University)
Publication Information
The Journal of Internal Korean Medicine / v.35, no.1, 2014 , pp. 70-78 More about this Journal
Abstract
Objectives : Hoechunyanggyeok-san (HYS) is a traditional herbal medicine, which has been clinically used for treating febrile and inflammatory diseases. HYS has been reported to be a useful treatment for diabetes, atherosclerosis and hyperlipidemia in the type 1 diabetic model. However, the mechanism of the effects of HYS against hyperglycemia and hyperlipidemia is poorly understood. In the present study, we investigated the underlying mechanism of ameliorative effect of HYS on hyperglycemia and hyperlipidemia in vivo. Methods : HYS (10, 50 mg/kg/day, p.o.) was administered every day for 2 weeks to db/db mice and its effect was compared with vehicle-treated db/db mice. To confirm serum glucose and triglyceride (TG) changes, serological testing was performed. The levels of sterol regulatory element-binding protein-1 (SREBP-1) activity and Sirtuin1 (SIRT1), AMP-activated protein kinase (AMPK), and acetyl-CoA carboxylase ${\alpha}$ ($ACC{\alpha}$) expression were analyzed by western blot analysis. Results : The administration of HYS significantly decreased the elevated serum glucose and TG in db/db mice. HYS administration increased the levels of SIRT1 and AMPK expression compared with the vehicle-treated group. Moreover, HYS treatment significantly inhibited SREBP-1 activity and $ACC{\alpha}$ expression in the liver, while the vehicle-treated group exhibited their increase. Conclusions : In conclusion, HYS is suggested to have an improvement effect on hyperglycemia and hyperlipidemia by activating the SIRT1/AMPK signaling pathway and inhibiting SREBP-1.
Keywords
Hoechunyanggyeok-san; hyperlipidemia; SIRT1; SREBP-1; $ACC{\alpha}$;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Heo JG. Jung-ui-bang-je-hak. Seoul: Eum- yang -maek-gin Publishing; 1991, p. 174-5.
2 Kim GJ, Kim JH, Chae BY. Anti-allergic and antiinflammatory analgesic effects of Hoechunyanggyeoksan. The J of Oriental Medical Surgery, Ophthalmology & Otolaryngology 1994;7(1):1-13.
3 Kang SW, No SS. Experimental study on the anti-inflammatory and wound healing effect of hoichunyanggyuksan and yongseksan. The J of Oriental Medical Surgery, Ophthalmology & Otolaryngology 1999;12(1):47-78.
4 Hwang TG, Shi S. Jung-yak-bang-je-hyun-dae -yeon-gu-dae-jeon. Baiging: Science Publishing; 1996, p. 1256.
5 Song IB. Sa-sang-ui-hak. Seoul: Jip-mun-dang; 1997, p. 397-8.
6 Marchi ED, Baldassari F, Bononi A, Wieckowski MR, Pinton P. Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and Protein Kniase C. Oxidative Medicine and Cellular Longevity 2013;1013:1-11.
7 Savini I., Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013;14:10497-537.   DOI   ScienceOn
8 Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002;366:377-91.   DOI   ScienceOn
9 Ferre P, Foretz M, Azzout-Marniche D, Becard D, Foufelle F. Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. Biochemical Society Transactions 2001;29(4):547-52.   DOI   ScienceOn
10 Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochemical Society Transactions 2001; 30(6):1091-5.   DOI
11 Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans 2002;30(6) :1059-64.
12 Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory elementbinding proteins. World J Gastroenterol 2004; 10(21):3081-7.
13 Lan F, Cacicedo JM., Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008;283(41):27628-35.   DOI   ScienceOn
14 Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Milne JC., Elliott PJ et al. AMPK regulates energy expenditure by modulating $NAD^{+}$ metabolism and SIRT1 activity. Nature 2009;458(7241):1056-60.   DOI   ScienceOn
15 Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40.   DOI   ScienceOn
16 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.   DOI
17 Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005;62(16) :1784-803.   DOI   ScienceOn
18 Walker AK, Yang FJ, Jiang KR, Ji JY, Watts JL et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes & Development 2010;24 :1403-17.   DOI   ScienceOn
19 Lee TH, Jo MJ, Park SJ, Lee JR, Back YD, Kim JR et al. Inhibitory effects of hoechunyanggyeok -san on inflammation in Vivo and in Vitro. Korean J Oriental Physiology & Pathology 2009; 23(6):1341-891.
20 Gong JH. Man-byeong-hoe-chun. Seoul: Haeng-rim -seo-won; 1972, p. 16.
21 Kim JH, Jo GJ, Choi GM, Han JH, Yoon DK, Kim SM. The relationship between plasma Visfatin level, obesity and metabolic syndrome in women without diabetes. Korean J Obes 2009;18(1):15-23.
22 Speigelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104(4) :531-43.   DOI   ScienceOn
23 Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic pontential. Diabetes Metab J 2013;37:315-25.   DOI   ScienceOn
24 Rodgers RJ, Tschop MH, Wilding JPH. Antiobesity drugs: past, present and future. Disease Models & Mechanisms 2012;5:621-6.   DOI
25 Hwang DY. Bang-yak-hap-pyeon. Seoul: Yeongrim- sa; 1985, p. 304-5.
26 Hong JS. Effect of Hoechounyanggeuksan on the glucose in diabetic rats induced by streptozotocin. J. of Oriental Medicine 1991;14:397-412.
27 Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K, Koya K. Sirtuins and renal disease: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013;124:153-64.   DOI
28 Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004;3:340-51.   DOI   ScienceOn
29 Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40.   DOI
30 Li Y, Xu SQ, Mihaylova MM, Zheng B, Hou XY et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabolism 2011;13:376-88.   DOI   ScienceOn